Details of HTA published project
Research type: |
NICE Technology Assessment Report (TAR) |
Title (lead author) etc: |
The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation (Pandor) 204 pages, Volume 10, number 41 |
Link to NICE guidance page |
|
DOI |
10.3310/hta10410 |
|
This publication is now a part of the NIHR Journals Library. Documents relating to the publication can be found at the corresponding journal issue page, which is at the following link: 
http://www.journalslibrary.nihr.ac.uk/hta/volume-10/issue-41
Outputs from this project
|
|
This report should be referenced as follows: |
Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Health Technol Assess 2006;10(41). |
Project ref: |
04/18/01 |
Original project title: |
The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation |
Chief Investigator: |
School of Health and Related Research (ScHARR-TAG), University of Sheffield |
Start Date: |
February 2005 |
Date of publication in HTA journal series (now NIHR Journals Library) |
November 2006 |
Cost: |
This project was commissioned by the HTA programme on behalf of the National Institute for Health and Clinical Excellence on a call-off contract basis |
MeSH* index primary terms: |
COLONIC-NEOPLASMS Q-drug-therapy; ANTINEOPLASTIC-COMBINED-CHEMOTHERAPY-PROTOCOLS Q-therapeutic-use; ANTINEOPLASTIC-COMBINED-CHEMOTHERAPY-PROTOCOLS Q-economics; ANTINEOPLASTIC-COMBINED-CHEMOTHERAPY-PROTOCOLS Q-adverse-effects (* = Medical Subject Headings) |
MeSH* index secondary terms: |
HUMANS; CHEMOTHERAPY-ADJUVANT; OXALIPLATIN Q-administration-&-dosage; FLUOROURACIL Q-administration-&-dosage; CAPECITABINE Q-administration-&-dosage; OXALIPLATIN Q-adverse-effects; FLUOROURACIL Q-adverse-effects; CAPECITABINE Q-adverse-effects; OXALIPLATIN Q-economics; FLUOROURACIL Q-economics; CAPECITABINE Q-economics; COST-BENEFIT-ANALYSIS; QUALITY-OF-LIFE; SURVIVAL-ANALYSIS; TREATMENT-OUTCOME (* = Medical Subject Headings) |
NRR* number, if applicable: |
N0484156273 (*National Research Register) The National Research Register was a public database of ongoing and recently completed research projects funded by, or of interest to, the United Kingdom's National Health Service (NHS). It is now an archive of projects from early 2000 to September 2007. Search the NRR archive. |
Project Protocol: |
Project protocol not available |
URL of this page: |
http://www.hta.ac.uk/1470 |
News feeds